Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
1.用于治疗达沙替尼或尼洛替尼治疗无效的慢性期、进展期或急性期的慢性粒细胞白血病(CML);或不能耐受达沙替尼或尼洛替尼者,以及临床不适合用伊马替尼进行后续治疗的患者;或T315I突变者。
2.用于治疗达沙替尼治疗无效的费城染色体阳性急性淋巴细胞白血病(Ph+ALL);或不能耐受达沙替尼者,以及临床不适合用伊马替尼进行后续治疗的患者;或T315I突变者。
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.